CRVO CervoMed Inc.
Company Analysis
Latest News
🟢 CervoMed is trading 6.25% up in after-hours trading with no clear catalyst identified
CervoMed is trading at $1.70, up 6.25% in after-hours trading, with no clear company-specific catalyst identified. - CervoMed’s October 29 research...
🔴 CervoMed is trading 6% down with no clear catalyst
CervoMed is trading -6.03% at $1.65, with no new company-specific catalyst clearly explaining the October 30 decline. - An October 29 research-publication...
🟢 CervoMed is trading 5% up in pre-market alongside healthcare's 1.32% pre-market gain
CervoMed is trading 5.14% higher at $1.84 in pre-market on October 30, alongside a 1.32% pre-market gain in healthcare; the available company news does not...
CervoMed Publishes Peer-Reviewed Data Supporting Neflamapimod for Dementia with Lewy Bodies
CervoMed announced the publication of two peer-reviewed research articles that provide further evidence for the potential of its drug candidate, neflamapimod,...
🔴 CervoMed is trading 6.9% down in after-hours trading after Phase 2b trial missed primary CDR-SB measure
CervoMed is trading 6.86% down at $1.63 after October 29 results showed its 159-patient Phase 2b RewinD-LB trial did not confirm the earlier Phase 2a result on...
🔴 CervoMed is trading 12.4% down after RewinD-LB failed to confirm primary outcome
CervoMed is trading 12.4% down at $1.94 after its 159-patient RewinD-LB Phase 2b study failed to confirm the earlier Phase 2a result on the primary measure,...
🔴 CervoMed is trading 6.3% down today after Phase 2b trial missed primary outcome
CervoMed is trading 6.3% lower at $2.07 after its Phase 2b RewinD-LB trial failed to confirm the primary outcome in the full study population. - Results from...
🔴 CervoMed is trading 5% down
CervoMed is trading 5.41% down at $2.19, and no clear catalyst was identified in the sources reviewed. - No company-specific announcement dated October 26,...
🟢 CervoMed is trading 5.7% up in pre-market amid positive initial Phase 2a biomarker data
CervoMed is trading 5.7% up in pre-market at $2.42, with positive initial Phase 2a biomarker data as context. - October 20 close: $2.29; no October 21 company...
CervoMed Retains Wainwright Buy Rating After Positive Phase 2a Data
On October 19, 2026, H.C. Wainwright reiterated its Buy rating and $25.00 price target for CervoMed Inc. The reaffirmation followed the company’s presentation...
🟢 CervoMed is trading 7.6% up in pre-market with no fresh catalyst identified
CervoMed is trading at $2.41, up 7.59%, in pre-market on October 19, with no fresh company-specific catalyst identified. - The October 16 close was $2.24. -...
🔴 CervoMed is trading 5% down; no company-specific cause identified
CervoMed is trading 5.29% down at $2.15, in a decline consistent with broader market pressure; no company-specific cause has been identified. -...
🟢 CervoMed is trading 5.7% up
CervoMed is trading 5.73% higher at $2.40 on October 14, 2026, with no company-specific announcement explaining the move identified in available coverage. -...
🔴 CervoMed is trading 10.9% down with no clear company-specific catalyst
CervoMed is trading at $2.24, down 10.88% on October 13; no clear company-specific explanation was found. - The October 12 update reported an early...
🔴 CervoMed is trading 5.6% down today with sector weakness a possible factor
CervoMed is trading at $2.37, down 5.58%, with healthcare-sector weakness a possible contributor that does not fully explain the decline. - Healthcare stocks...
CervoMed Reports Positive Initial Phase 2a Data for Neflamapimod in nfvPPA Trial
CervoMed Inc. announced positive initial data from the first 12 weeks of its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive...
🔴 CervoMed is trading 14% down — no confirmed catalyst
CervoMed is trading at $2.78, a -13.67% change, with no confirmed explanation for the decline. - As of October 12, 2026, no clearly confirmed company...
🔴 CervoMed is trading 13% down in pre-market with no clear catalyst identified
CervoMed is trading at $2.80, with a -13.04% change; no clearly linked new company announcement was identified to explain the decline. - CervoMed was...
🔴 CervoMed is trading 5% down today amid broad market weakness
CervoMed is trading at $3.17, down 5.24%, as broader risk-off sentiment provides the clearest available context for the decline. - No new company-specific...
🟢 CervoMed is trading 5% up in pre-market with no identified company catalyst
CervoMed is trading at $3.49, up 5.44% in pre-market versus its October 5 close of $3.31; no new company announcement explaining the move was identified. -...